Lorinda Chung

Rheumatologist, Immunologist

Associate Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Dermatology at the Palo Alto Veterans Affairs Health Care Center

Autoimmune Skin Disease Clinic

  • 450 Broadway Street
  • Redwood City, CA 94063
  • Phone: 650-723-6316
Learn More About the Clinic Getting Here Make An Appointment

Immunology and Rheumatology Clinic

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-6961
Learn More About the Clinic Getting Here Make An Appointment

Psoriasis Clinic

  • 450 Broadway Street
  • Redwood City, CA 94063
  • Phone: 650-723-6316
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University School of Medicine (2006) CA

Board Certification: Rheumatology, American Board of Internal Medicine (2005)

Residency: Stanford University School of Medicine (2003) CA

Medical Education: Ohio State University College of Medicine (2000) OH

AB, Princeton University, Molecular Biology (1996)

MD, Ohio State University, Medicine (2000)

MS, Stanford University, Epidemiology (2007)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: Results of a prospective pilot study.
Chung, L., Ball, K., Yaqub, A., Lingala, B., & Fiorentino, D. (2014). Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: Results of a prospective pilot study. Journal of the American Academy of Dermatology, 71(2), 400-401.

Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
Hsu, V. M., Chung, L., Hummers, L. K., Wigley, F., Simms, R., & Steen, V. D. (2014). Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars in arthritis and rheumatism, 44(1), 55-62.

Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
Valenzuela, A., Chung, L., Casciola-Rosen, L., & Fiorentino, D. (2014). Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA dermatology, 150(7), 724-729.

Cardiac arrhythmias and conduction defects in systemic sclerosis
Vacca, A., Meune, C., Gordon, J., Chung, L., Proudman, S., & Allanore, Y. (2014). Cardiac arrhythmias and conduction defects in systemic sclerosis. RHEUMATOLOGY, 53(7), 1172-1177.

Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria
Johnson, S. R., Naden, R. P., Fransen, J., van den Hoogen, F., Pope, J. E., & Khanna, D. (2014). Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. JOURNAL OF CLINICAL EPIDEMIOLOGY, 67(6), 706-714.

Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Chung, L., Domsic, R. T., Lingala, B., Alkassab, F., Bolster, M., & Steen, V. D. (2014). Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. ARTHRITIS CARE & RESEARCH, 66(3), 489-495.

Atherosclerotic Cardiovascular Disease in Hospitalized Patients With Systemic Sclerosis: Higher Mortality Than Patients With Lupus and Rheumatoid Arthritis
Dave, A. J., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2014). Atherosclerotic Cardiovascular Disease in Hospitalized Patients With Systemic Sclerosis: Higher Mortality Than Patients With Lupus and Rheumatoid Arthritis. ARTHRITIS CARE & RESEARCH, 66(2), 323-327.

International consensus criteria for the diagnosis of Raynaud's phenomenon
Maverakis, E., Patel, F., Kronenberg, D. G., Chung, L., Fiorentino, D., & Gershwin, M. E. (2014). International consensus criteria for the diagnosis of Raynaud's phenomenon. JOURNAL OF AUTOIMMUNITY, 48-49, 60-65.

Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis
Baron, M., Chung, L., Gyger, G., Hummers, L., Khanna, D., & Hudson, M. (2014). Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. CLINICAL RHEUMATOLOGY, 33(2), 207-214.

Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Khanna, D., Gladue, H., Channick, R., Chung, L., Distler, O., & McLaughlin, V. V. (2013). Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. ARTHRITIS AND RHEUMATISM, 65(12), 3194-3201.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?.
Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., & Casciola-Rosen, L. (2013). Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?. Arthritis and rheumatism, 65(11), 2954-2962.

Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?.
Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., & Casciola-Rosen, L. (2013). Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?. Arthritis and rheumatism, 65(11), 2954-2962.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., & Pope, J. E. (2013). 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. ANNALS OF THE RHEUMATIC DISEASES, 72(11), 1747-1755.

2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., & Pope, J. E. (2013). 2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. ARTHRITIS AND RHEUMATISM, 65(11), 2737-2747.

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry
Barst, R. J., Chung, L., Zamanian, R. T., Turner, M., & Mcgoon, M. D. (2013). Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry. CHEST, 144(1), 160-168.

Localized Cutaneous Fibrosing Disorders
Yaqub, A., Chung, L., Rieger, K. E., & Fiorentino, D. F. (2013). Localized Cutaneous Fibrosing Disorders. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 39(2), 347-?.

Localized cutaneous fibrosing disorders.
Yaqub, A., Chung, L., Rieger, K. E., & Fiorentino, D. F. (2013). Localized cutaneous fibrosing disorders. Rheumatic diseases clinics of North America, 39(2), 347-364.

Management of the hand in systemic sclerosis.
Fox, P., Chung, L., & Chang, J. (2013). Management of the hand in systemic sclerosis. journal of hand surgery, 38(5), 1012-1016.

Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire.
Chung, L., Chen, H., Khanna, D., & Steen, V. D. (2013). Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire. Arthritis care & research, 65(3), 454-463.

Epidemiology and Risk Factors for Pulmonary Hypertension in Systemic Sclerosis
Yaqub, A., & Chung, L. (2013). Epidemiology and Risk Factors for Pulmonary Hypertension in Systemic Sclerosis. CURRENT RHEUMATOLOGY REPORTS, 15(1).

Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey
Linos, E., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2013). Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. ARTHRITIS RESEARCH & THERAPY, 15(1).

Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients.
Fiorentino, D., Chung, L., Zaba, L., Lingala, B., Rosen, A., & Casciola-Rosen, L. (2012). Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients. ARTHRITIS AND RHEUMATISM, 64(10), S828-S828.

Clinical presentation and evaluation of dermatomyositis.
Marvi, U., Chung, L., & Fiorentino, D. F. (2012). Clinical presentation and evaluation of dermatomyositis. Indian journal of dermatology, 57(5), 375-381.

Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry
Bae, S., Saggar, R., Bolster, M. B., Chung, L., Csuka, M. E., & Khanna, D. (2012). Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. ANNALS OF THE RHEUMATIC DISEASES, 71(8), 1335-1342.

Hyperuricemia in Young Adults and Risk of Insulin Resistance, Prediabetes, and Diabetes: A 15-Year Follow-up Study
Krishnan, E., Pandya, B. J., Chung, L., Hariri, A., & Dabbous, O. (2012). Hyperuricemia in Young Adults and Risk of Insulin Resistance, Prediabetes, and Diabetes: A 15-Year Follow-up Study. AMERICAN JOURNAL OF EPIDEMIOLOGY, 176(2), 108-116.

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
Fransen, J., Johnson, S. R., van den Hoogen, F., Baron, M., Allanore, Y., & Khanna, D. (2012). Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. ARTHRITIS CARE & RESEARCH, 64(3), 351-357.

Clinical trial design in scleroderma: where are we and where do we go next?
Chung, L., Denton, C. P., Distler, O., Furst, D. E., Khanna, D., & Merkel, P. A. (2012). Clinical trial design in scleroderma: where are we and where do we go next?. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 30(2), S97-S102.

A Pilot Study of Abatacept for the Treatment of Patients with Diffuse Cutaneous Systemic Sclerosis.
Chakravarty, E. F., Fiorentino, D., Bennett, M., & Chung, L. (2011). A Pilot Study of Abatacept for the Treatment of Patients with Diffuse Cutaneous Systemic Sclerosis. ARTHRITIS AND RHEUMATISM, 63(10), S274-S275.

Tyrosine kinases in inflammatory dermatologic disease
Paniagua, R. T., Fiorentino, D. F., Chung, L., & Robinson, W. H. (2011). Tyrosine kinases in inflammatory dermatologic disease. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(2), 389-403.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study
Fiorentino, D., Chung, L., Zwerner, J., Rosen, A., & Casciola-Rosen, L. (2011). The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(1), 25-34.

Pathogenesis of dermatomyositis: role of cytokines and interferon.
Kao, L., Chung, L., & Fiorentino, D. F. (2011). Pathogenesis of dermatomyositis: role of cytokines and interferon. Current rheumatology reports, 13(3), 225-232.

An Analysis of Connective Tissue Disease-associated Interstitial Lung Disease at a US Tertiary Care Center: Better Survival in Patients with Systemic Sclerosis
Su, R., Bennett, M., Jacobs, S., Hunter, T., Bailey, C., & Chung, L. (2011). An Analysis of Connective Tissue Disease-associated Interstitial Lung Disease at a US Tertiary Care Center: Better Survival in Patients with Systemic Sclerosis. JOURNAL OF RHEUMATOLOGY, 38(4), 693-701.

Colonic ulceration as an unusual manifestation of vasculopathy in systemic sclerosis
Kao, L., Myer, P., Nguyen, L., Zamanian, R. T., & Chung, L. (2011). Colonic ulceration as an unusual manifestation of vasculopathy in systemic sclerosis. RHEUMATOLOGY, 50(3), 626-628.

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.
Arefiev, K., Fiorentino, D. F., & Chung, L. (2011). Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. International journal of rheumatology, 2011, 201787-?.

Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study
Krishnan, E., Pandya, B. J., Chung, L., & Dabbous, O. (2011). Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study. ARTHRITIS RESEARCH & THERAPY, 13(2).

Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL Identifying Systemic Sclerosis as a Unique Phenotype
Chung, L., Liu, J., Parsons, L., Hassoun, P. M., McGoon, M., & Zamanian, R. T. (2010). Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL Identifying Systemic Sclerosis as a Unique Phenotype. CHEST, 138(6), 1383-1394.

A 39-Year-Old Woman With Lupus, Myositis, and a Recalcitrant Vasculopathy
Sokolove, J., Copland, A., Shirvani, S., Brown, J., Posley, K., & Chung, L. (2010). A 39-Year-Old Woman With Lupus, Myositis, and a Recalcitrant Vasculopathy. ARTHRITIS CARE & RESEARCH, 62(9), 1351-1356.

Evaluation of an imatinib response gene signature in patients with systemic sclerosis
Chung, L., Ruiz, P., Wood, T., Shoor, S., Robinson, W., & Fiorentino, D. (2010). Evaluation of an imatinib response gene signature in patients with systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28(5), S62-S62.

Digital ischemic loss in systemic sclerosis.
Marvi, U., & Chung, L. (2010). Digital ischemic loss in systemic sclerosis. International journal of rheumatology.

Vascular disease in systemic sclerosis.
Chung, L., Distler, O., Hummers, L., Krishnan, E., & Steen, V. (2010). Vascular disease in systemic sclerosis. International journal of rheumatology, 2010, 714172-?.

Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients
Schmajuk, G., Bush, T. M., Burkham, J., Krishnan, E., & Chung, L. (2009). Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27(3), S22-S25.

Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients.
Schmajuk, G., Bush, T. M., Burkham, J., Krishnan, E., & Chung, L. (2009). Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanic patients. Clinical and experimental rheumatology, 27(3), 22-25.

MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial
Chung, L., Shapiro, L., Fiorentino, D., Baron, M., Shanahan, J., & Wigley, F. M. (2009). MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial. ARTHRITIS AND RHEUMATISM, 60(3), 870-877.

Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis
Chung, L., Fiorentino, D. F., Benbarak, M. J., Adler, A. S., Mariano, M. M., & Robinson, W. H. (2009). Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis. ARTHRITIS AND RHEUMATISM, 60(2), 584-591.

Malignancy in the Setting of the Anti-Synthetase Syndrome
Rozelle, A., Trieu, S., & Chung, L. (2008). Malignancy in the Setting of the Anti-Synthetase Syndrome. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 14(5), 285-288.

Molecular framework for response to imatinib mesylate in systemic sclerosis
Chung, L., Fiorentino, D. F., Benbarak, M. J., Adler, A. S., Mariano, M. M., & Robinson, W. H. (2008). Molecular framework for response to imatinib mesylate in systemic sclerosis. ARTHRITIS AND RHEUMATISM, 58(9), S819-S820.

Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease
Chakravarty, E. F., Khanna, D., & Chung, L. (2008). Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. OBSTETRICS AND GYNECOLOGY, 111(4), 927-934.

Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample
Chung, L., Krishnan, E., & Chakravarty, E. F. (2007). Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. RHEUMATOLOGY, 46(12), 1808-1813.

A pilot trial of rituximab in the treatment of patients with dermatomyositis
Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763-767.

Therapeutic options for digital ulcers in patients with systemic sclerosis.
Chung, L. (2007). Therapeutic options for digital ulcers in patients with systemic sclerosis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 5(6), 460-465.

A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands
Magnano, M. D., Chakravarty, E. F., Broudy, C., Chung, L., Kelman, A., & Genovese, M. C. (2007). A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. JOURNAL OF RHEUMATOLOGY, 34(6), 1323-1327.

Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease.
Chung, L., Flyckt, R. Lr., Colon, I., Shah, A. A., Drusin, M., & Chakravarty, E. F. (2006). Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. ARTHRITIS AND RHEUMATISM, 54(12), 4077-4077.

Successful use of rituximab for cutaneous vasculitis
Chung, L., Funke, A. A., Chakravarty, E. F., Callen, J. P., & Fiorentino, D. F. (2006). Successful use of rituximab for cutaneous vasculitis. ARCHIVES OF DERMATOLOGY, 142(11), 1407-1410.

Systemic and locatized scleroderma
Chung, L., Lin, J., Furst, D. E., & Fiorentino, D. (2006). Systemic and locatized scleroderma. CLINICS IN DERMATOLOGY, 24(5), 374-392.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis
Chung, L., & Fiorentino, D. (2006). A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 54(5), 880-882.

Digital ulcers in patients with systemic sclerosis
Chung, L., & Fiorentino, D. (2006). Digital ulcers in patients with systemic sclerosis. AUTOIMMUNITY REVIEWS, 5(2), 125-128.

Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease
Chung, L., Flyckt, R. Lr., Colon, I., Shah, A. A., Druzin, M., & Chakravarty, E. F. (2006). Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. LUPUS, 15(9), 595-599.

Bleeding complications in patients on celecoxib and warfarin
Chung, L., Chakravarty, E. F., Kearns, P., Wang, C., & Bush, T. M. (2005). Bleeding complications in patients on celecoxib and warfarin. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 30(5), 471-477.

Giant cell myocarditis: a rare cardiovascular manifestation in a patient with systemic lupus erythematosus.
Chung, L., Berry, G. J., & Chakravarty, E. F. (2005). Giant cell myocarditis: a rare cardiovascular manifestation in a patient with systemic lupus erythematosus. Lupus, 14(2), 166-169.

Incidence of bleeding complications in patients on celecoxib and warfarin.
Chung, L., Wang, C., Kearns, P., Chakravarty, E. F., & Bush, T. M. (2004). Incidence of bleeding complications in patients on celecoxib and warfarin. ARTHRITIS AND RHEUMATISM, 50(12), 4087-4088.

Antibodies in scleroderma: direct pathogenicity and phenotypic associations.
Chung, L., & Utz, P. J. (2004). Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Current rheumatology reports, 6(2), 156-163.